Lubiprostone phase 3 double-blind study

Multi-center, randomized, parallel-group, double-blind, placebo-controlled study to evaluate the safety and efficacy of lubiprostone in patients with chronic idiopathic constipation (CIC)

Status

Unknown

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080220730

Enrollment

116

Registered

2009-05-12

Start date

2009-05-12

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic idiopathic constipation

Interventions

investigational material(s) Generic name etc : lubiprosotne INN of investigational material : Therapeutic category code : 239 Other agents affecting digestive organs Dosage and Administration for Inv

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: history of fewer than three spontaneous bowl movements (SBMs) per week for at least six months

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
change in SBMs at the end of the first week of treatment	—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026